Izquierdo et al., 2022, Cancer Discov. DOI: 10.1158/2159-8290.CD-20-0930
Mitogen-activated protein kinase (MAPK) pathway alterations are commonly found in childhood cancer, particularly brain tumors, and especially low- and high-grade gliomas. Although targeted agents against the MAPK pathway (inhibitors targeting BRAF – vemurafenib, dabrafenib and MEK – trametinib, selumetinib, cobimetinib) have become an important initial success story in the field of precision oncology, they are frequently associated with the emergence of resistance and treatment failure.
continue reading